Results 191 to 200 of about 99,253,553 (299)

Do Intoxicated Offenders Deserve Harsher Sentences? Questioning Veritas in Vino

Journal of Social Philosophy, EarlyView.
ABSTRACT Criminal courts increasingly treat intoxication as an aggravating rather than a mitigating factor in sentencing. This shift, seen in Australian law and other jurisdictions, raises the prospect of unjust outcomes. We examine this trend through the lens of desert‐based justifications for punishment, setting aside questions of deterrence and ...
Mary Jean Walker, Daniel B. Cohen
wiley   +1 more source

Case Report: NEUROD1 c.-108G>C mutation in a ketosis-prone MODY6 patient: implications for genetic testing and DPP-4 inhibitor therapy. [PDF]

Front Endocrinol (Lausanne)
Shao Z, Xu L.
europepmc   +1 more source

Incretin‐Based Medications in Women and Reproduction: A Systematic Scoping Review and Consensus Guidelines for Clinical Practice

Obesity Reviews, EarlyView.
ABSTRACT Introduction Pregnancy concurrent with incretin‐based medications is contraindicated due to unknown risk of teratogenicity, as is breastfeeding. The aim of this systematic scoping review was to investigate potential risks and benefits of incretin‐based medications in relation to preconception, pregnancy, and postnatal health, and to propose ...
Kate Maslin, Jill Shawe, Sinead Blowers, Michael Ceulemans, Kathryn Hart, Sam Schoenmakers, Amihai Rottenstreich, Heather Hopper, Mojca Jensterle, Angela C. Flynn, Sarah Siegelaar, Annick Bogaerts, Isy Douek, Nicola Heslehurst, Dries Ceulemans, Tricia Tan, Johnathan Pinkney, Martin Whyte, Shahrad Taheri, Roland Devlieger   +19 more
wiley   +1 more source

Targeting Overweight and Obesity Phenotypes for Secondary Prevention of Cardiovascular Disease: A Call to Action for the Middle East and Beyond

Obesity Reviews, EarlyView.
ABSTRACT Although there are conflicting clinical data on the efficacy of weight reduction in reducing secondary events in patients with comorbid overweight and obesity (OAO) and cardiovascular disease (CVD), there is excellent epidemiological and biological evidence of a cause–effect relationship between OAO, CVD, and other systemic complications ...
Wael Almahmeed, Juan S. Barajas‐Gamboa, Mohammad Zubaid, Ebaa Al Ozairi, Abdullah Shehab, Khalid Al‐Rasadi, Charbel Abi Khalil, Noor Al Busaidi, Fahad Al Sindi, Zuhier Awan, Tomader Ali, Khaldoon Al‐Humood, Fatheya Al Awadi, Mohammed Al Hadad, Manal Al Kindi, Khalid Al Habib, Khalid Al Waili, Maryam Alsaeed, Adel Tash, Hani Sabbour   +19 more
wiley   +1 more source

Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025). [PDF]

Diabetes Obes Metab
Yu M, Wang T, Xu C, Bi Y, Gao L, Wang G, Xiang G, Xue Y, Yang T, Kang D, Zhou Z, Guo L, Xiao X, Steering Committee, Development Group, Diabetes Committee of the Chinese Research Hospital Association.   +15 more
europepmc   +1 more source

Toward “Obesityomics”: Domain‐Specific Omics in Precision Obesity Medicine with a Brief AI Perspective

Obesity Reviews, EarlyView.
ABSTRACT Background Obesity's global rise has outpaced the effectiveness of “one‐size‐fits‐all” prevention and treatment strategies. The promise of precision medicine lies in addressing the etiological and biological diversity of obesity and transforming it into actionable endotypes.
Nadia Abu Samra, Sara G. I. Suliman, Mohammed Al‐Hadad, Dorret I. Boomsma, Fadwa Alhantoobi, Maithah Alsamahi, Haneen Abufarajallah, Alia Al Tikriti, Zeyar Aung, Selena Richards, Abdulrahim Sajini, Mira Mousa, Fatima Sulaiman, Wael Osman   +13 more
wiley   +1 more source

Euglycemic DKA in a DPP-4 inhibitor patient following traumatic brain injury: A complex ICU glucose management challenge. [PDF]

Medicine (Baltimore)
Shammas I, Seyaj M, Altell K, Sobeih R, Asafrah L, Burqan M, Abuhalawa M, Shahateet M, Itkaidek S.   +8 more
europepmc   +1 more source

GLP‐1 Receptor Agonists and Cancer Risk in Obesity Treatment

Obesity Reviews, EarlyView.
ABSTRACT Obesity is a well‐established risk factor for numerous cancers, with body habitus, especially central adiposity, contributing to increased cancer incidence and worse prognosis. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially developed to treat Type 2 diabetes, have rapidly gained prominence as powerful anti‐obesity agents due ...
Lorne J. Hofseth, E. Angela Murphy, Mary C. Playdon, Liza Makowski, Anna R. Ibele, Ciaran M. Fairman, James R. Hebert   +6 more
wiley   +1 more source

A Comparison of SGLT2 or DPP-4 Inhibitor Monotherapy vs Placebo for Type 2 Diabetes in Adolescents vs Young Adults. [PDF]

J Endocr Soc
Laffel LM, Danne T, Klingensmith GJ, Schueler E, Tartakovsky I, Nessralla L, Zeitler P, Willi S.   +7 more
europepmc   +1 more source

Periodontal Therapy–Related Changes in Clinical Parameters, Active‐Matrix Metalloproteinase‐8 and C‐Reactive Protein in Prediabetes and Diabetes

Oral Diseases, EarlyView.
ABSTRACT Objectives This study investigated the effect of nonsurgical periodontal therapy (NSPT) on periodontal clinical parameters, active‐matrix metalloproteinase‐8 (aMMP‐8), high sensitivity C‐reactive protein (hsCRP), and glycated hemoglobin (HbA1c), and their relationships in diabetes and prediabetes patients with periodontitis.
Kehinde Adesola Umeizudike, Olayiwola Ibrahim Olaoye, Ayodele Charles Ogundana, Ismo T. Räisänen, Solomon Olusegun Nwhator, Babatunde Yusuf Alli, Patricia Omowunmi Ayanbadejo, Olufemi Adetola Fasanmade, Timo Sorsa   +8 more
wiley   +1 more source